logo
logo

Amgen To Acquire Chemocentryx For $4 Billion In Cash

Amgen To Acquire Chemocentryx For $4 Billion In Cash

08/04/22, 12:12 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgthousand oaks
Industry
biotechnology
health care
therapeutics
pharmaceutical
biotechnology
health care
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.

Company Info

Company
Amgen
Location
Thousand Oaks, California, United States
Company info
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Related People